Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ownership Breakdown Revance Therapeutics Inc. RVNC

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are Product and the Service Segment. The Products segment generates maximum revenue which is engaged in the research and development of aesthetic and therapeutic products.


Top institutional share ownership of Revance Therapeutics Inc

Name Shares Shares % change Value Value % change
Jpmorgan Chase & Co 6,687,925 -1.9% $92,427 -30.5%
BlackRock Inc. 5,684,831 7.5% $78,564 -23.8%
Capital World Investors 4,590,000 37.0% $63,434 -2.9%
SMCWX - SMALLCAP WORLD FUND INC Class A 4,590,000 -6.2% $63,434 -33.6%
Palo Alto Investors LP 4,405,039 -0.2% $60,878 -29.3%
Vanguard Group Inc 3,703,055 1.6% $51,176 -28.0%
Polar Capital Holdings Plc 3,117,052 26.9% $43,078 -10.1%
Franklin Resources Inc 2,366,367 6.9% $32,703 -24.2%
OGGFX - JPMorgan Small Cap Growth Fund Class I 2,270,173 2.7% $31,374 -27.2%
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares 2,020,705 0.8% $27,926 -28.6%

Top institutional buyers of Revance Therapeutics Inc

Name Shares % change Value % change Shares Value
Capital World Investors 37.0% -2.9% 4,590,000 $63,434
Polar Capital Holdings Plc 26.9% -10.1% 3,117,052 $43,078
Goldman Sachs Group Inc 26.3% -10.5% 828,925 $11,456
Bamco Inc /ny/ 20.9% -14.3% 1,683,008 $23,259
Citadel Advisors Llc 15.7% -18.0% 769,584 $10,635
State Street Corp 15.5% -18.2% 1,779,793 $24,597
FSGRX - Franklin Small Cap Growth Fund Class A 14.4% 8.4% 1,111,592 $17,252
BlackRock Inc. 7.5% -23.8% 5,684,831 $78,564
Franklin Resources Inc 6.9% -24.2% 2,366,367 $32,703
OGGFX - JPMorgan Small Cap Growth Fund Class I 2.7% -27.2% 2,270,173 $31,374

Top institutional sellers of Revance Therapeutics Inc

Name Shares % change Value % change Shares Value
Jennison Associates Llc -28.1% -49.0% 1,755,703 $24,264
Geode Capital Management, Llc -7.4% -34.4% 1,236,952 $17,094
SMCWX - SMALLCAP WORLD FUND INC Class A -6.2% -33.6% 4,590,000 $63,434
D. E. Shaw & Co., Inc. -3.4% -31.5% 817,740 $11,302
Rice Hall James & Associates, Llc -2.4% -30.9% 1,085,340 $14,999
Jpmorgan Chase & Co -1.9% -30.5% 6,687,925 $92,427
Fmr Llc -1.4% -30.1% 1,214,318 $16,782
HighTower Advisors, LLC -0.7% -29.7% 1,224,162 $16,917
HealthCor Management, L.P. -0.4% -29.4% 1,418,088 $19,598
Palo Alto Investors LP -0.2% -29.3% 4,405,039 $60,878

Information provided by Fintel.io